Navigation Links
Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
Date:9/14/2009

Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application submission in early 2010.

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose). Both product candidates are being developed for the acute treatment of migraine headache.

AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential and safety of AZ-104. Any statement describing a product candidate or Alexza's goals, expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertai
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Kepner-Tregoe (KT), the ... that 13-year veteran Chris Geraghty ... experience includes more than 20 years serving the ... manufacturing organizations. He succeeds Ray Baxter ... Kepner-Tregoe,s Chairman of the Board and CEO. ...
(Date:5/21/2013)... , May 21, 2013  IsoRay, Inc. (AMEX: ... it has entered into an exclusive international distribution agreement ... product line in Greece . IsoRay ... brachytherapy and medical radioisotope applications for brain cancer, lung ... ("gyn") cancer. IASIS Medical is ideally ...
(Date:5/21/2013)... , May 21, 2013  Vasomedical, Inc. (OTC BB: VASO) ... design, manufacture and sale of medical devices and in the ... Jun Ma , President and CEO of ... MicroCap Conference on Thursday, May 30, 2013 in ... The Company,s presentation is scheduled to begin ...
Breaking Medicine Technology:Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2
... N.Y., Sept. 9 Misonix, Inc. (Nasdaq: ... the art, ultrasonic medical device technology, which worldwide ... into a new, three year, exclusive distribution agreement ... will sell and distribute the SonaStar® Ultrasonic Surgical ...
... video detailing has made a strong comeback after ... and healthcare market research company Manhattan Research,s ... detailing has more than doubled in the past two years, ... self-report that their prescribing behavior is influenced by these programs, ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement For Spain 2Misonix Announces New Distribution Agreement For Spain 3New Study: Physician Adoption of Live Video Detailing Has Doubled Since 2008, But Will Likely Plateau Until 2012 as Pharma Optimizes Targeting 2New Study: Physician Adoption of Live Video Detailing Has Doubled Since 2008, But Will Likely Plateau Until 2012 as Pharma Optimizes Targeting 3
(Date:5/21/2013)... The Special Olympics Missouri State Summer Games will bring more ... Columbia. This state-level event takes place May 30-June 2, on ... and at Hickman High School and Town & Country Lanes. ... 7:30 p.m. Friday, May 30 with the Opening Ceremony. The ... of Athletes, the culmination of the statewide Law Enforcement Torch ...
(Date:5/21/2013)... significantly more likely than their normal-weight counterparts to ... disrupts continuity of care and leads to more ... , The practice of "doctor shopping" among overweight ... with the health care system, whether that be ... advice by providers, or improperly sized medical equipment ...
(Date:5/21/2013)... May 21, 2013 Children using ... Sophono, Inc., experience audiological results comparable to the ... many fewer complications, according to a new study. ... that Sophono’s abutment-free technology performs just as well ... with many fewer complications,” says Jim Kasic, president ...
(Date:5/21/2013)... 21 (HealthDay News) -- Urban elementary school children ... sleep problems and suffer academically, new research indicates. ... seven to nine, we found that compromised lung ... impaired academic performance," said study author Daphne ... behavior at Brown University,s Alpert Medical School in ...
(Date:5/21/2013)... Positively charged gold nanoparticles are usually toxic to ... nanoparticle toxicity. Mayo Clinic researchers found out why, ... against ovarian cancer cells. The discovery is detailed ... Journal of Biological Chemistry ., "This study identifies ... by preventing the cell death or apoptosis which ...
Breaking Medicine News(10 mins):Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 2Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 3Health News:'Doctor shopping' by obese patients negatively affects health 2Health News:'Doctor shopping' by obese patients negatively affects health 3Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 2Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 3Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2
... WM Healthcare Solutions, Inc. (WMHS), a subsidiary ... has purchased substantially all of the assets of ... pharmaceutical waste management consulting services to the U.S. ... other custom consulting services, in addition to the ...
... World Voice Day, April 16, 2009) NEW YORK, April 16 ... musical theater singers in the New York area received a ... cords in April at the second annual free Voice Screening ... Eye and Ear Infirmary and MusiCares, the charitable ...
... run the 2009 Bank of America Chicago Marathon on October 11th with ... is approaching, so please apply by April 20th, 2009 at www.ChristopherReeve.org/TeamReeve ... ... Chicago Chapter of the Christopher & Dana Reeve Foundation announces the ...
... Launches ORBIT, Open-Source Robotic Biorepository & Informatics Technology MILWAUKEE, April 15 , ... Informatics Technology, ... developing ... library of blood samples and privacy-protected ...
... 15 Fundacion Azteca in Mexico and,Fundacion Azteca ... join efforts to,commemorate the 50th Movimiento Azteca. ... conglomerate founded by entrepreneur Ricardo B. Salinas.,Through a ... and,funds to improve the well-being of both mother ...
... always been a brand about lifting spirits and lending their happy ... the brand,s 50th Anniversary celebration, nine celebrity mothers have united for ... Cause . The celebrity designers include: ... Paltrow, Catherine Bell, Elisabeth Hasselbeck and Garcelle Beauvais-Nilon . ...
Cached Medicine News:Health News:Waste Management Subsidiary Acquires PharmEcology(R) Associates, LLC 2Health News:Singers Hit High Notes in Free Voice Screening at The New York Eye and Ear Infirmary 2Health News:Attention Runners: Run the 2009 Bank of America Chicago Marathon with Team Reeve 2Health News:Attention Runners: Run the 2009 Bank of America Chicago Marathon with Team Reeve 3Health News:Fundacion Azteca and Fundacion Azteca America Present 50th Movimiento Azteca to Increase Awareness and Raise Funds for Prenatal and Natal Care 2Health News:Fundacion Azteca and Fundacion Azteca America Present 50th Movimiento Azteca to Increase Awareness and Raise Funds for Prenatal and Natal Care 3Health News:Lilly Pulitzer(R) Launches A Colorful Cause Celebrity Designed Collection for EBMRF 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: